NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily
oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]
#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment
Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 7 wks
Merck Could Strike 30 Billion Deal for Revolution Medicines / OncoDaily
oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment
Monday, January 12, 2026, 1:21 am / permalink 17767 / 2 stories in 1 month
Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals / MedCity
Frank Vinluan / medcitynews - Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Akt…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 10, 2026, 10:21 am / permalink 17733 / 8 stories in 2 months
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints
Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months
Low-dose peanut therapy shown to protect children with peanut allergies / Medical Express
medicalxpress - Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection against peanuts, finds a new study led by The Hospital for Sick Children (SickKids) and Montreal Children's Hospital.
#healthcare #publichealth #biotech #drugdevelopment
Saturday, January 3, 2026, 5:21 pm / permalink 17464 / 3 stories in 2 months
Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer / OncoDaily
oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer / Endpoints
Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...
#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, December 27, 2025, 6:20 am / permalink 17306 / 7 stories in 2 months
Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug / Endpoints
Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #vaccinesafety
Saturday, December 27, 2025, 2:21 am / permalink 17302 / 3 stories in 2 months
FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer / OncoDaily
oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Saturday, December 20, 2025, 9:20 pm / permalink 17185 / 13 stories in 2 months
Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 / OncoDaily
oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]
#healthcare #pharmaceuticals #elililly #biotech #drugdevelopment
Monday, December 15, 2025, 4:22 am / permalink 16960 / 2 stories in 2 months
FDA approves 1st gene therapy for Wiskott-Aldrich syndrome / Beckers
Ella Jeffries / beckershospitalreview - The FDA has approved Waskyra (etuvetidigene autotemcel), the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening immune disorder. Waskyra is indicated for pediatric patients 6 months and older, as well as adults with Wiskott-Aldri…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, December 15, 2025, 2:21 am / permalink 16954 / 4 stories in 2 months
Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial / American Association for Cancer Research
Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Wednesday, December 10, 2025, 11:22 am / permalink 16789 / 15 stories in 3 months
Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder / MedCity
Frank Vinluan / medcitynews - Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed t…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, December 6, 2025, 10:21 am / permalink 16661 / 2 stories in 3 months
A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes / Fierce
fiercehealthcare - Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from 12 former commissioners of the agency.
#healthcare #publichealth #governmentpolicy #biotech #drugdevelopment #fda #vaccinesafety
Thursday, December 4, 2025, 10:23 am / permalink 16565 / 10 stories in 3 months
FDA approves all ages gene therapy for spinal condition / Beckers
Ella Jeffries / beckershospitalreview - The FDA approved Novartis’ Itvisma (onasemnogene abeparvovec-brve), the company’s first and only gene replacement therapy for spinal muscular atrophy in children 2 and older, as well as for teens and adults. The therapy is designed to address the genetic …
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, December 1, 2025, 4:21 am / permalink 16428 / 2 stories in 3 months
Novo submits high-dose Wegovy for FDA approval using voucher / Endpoints
Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment #fda
Saturday, November 29, 2025, 5:21 pm / permalink 16400 / 2 stories in 3 months
Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials / Beckers
Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment
Tuesday, November 25, 2025, 10:21 am / permalink 16294 / 5 stories in 3 months
New nasal nanodrops wipe out brain tumors in mice / Science Daily Cancer
sciencedaily - A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune pathway using gold-core spherical nucleic acids, researchers were able to reach the brain without invasive surgery. When paired with dru…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, November 22, 2025, 1:21 pm / permalink 16217 / 3 stories in 3 months
FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation / ESMO
esmo - Evidence for efficacy is based on the results from the KO-MEN-001 study
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Saturday, November 22, 2025, 9:22 am / permalink 16210 / 2 stories in 3 months
Novo Nordisk rolls out lower prices for Ozempic and Wegovy / Medical Express
medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.
#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #publichealth #biotech
Thursday, November 20, 2025, 1:22 am / permalink 16131 / 6 stories in 3 months